Y-mAbs Therapeutics (YMAB) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

YMAB Y-mAbs Therapeutics

Watchlist

9.430
-0.340-3.48%

Close Dec 13 16:00 ET

9.430
0.0000.00%

Post 16:20 ET

422.36MMarket Cap-17.46P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Moomoo News15:31 ET · Ratings
Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics
TipRanksDec 11 06:26 ET · Ratings
CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
Moomoo NewsDec 9 08:31 ET · Ratings
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs TherapeuticsDec 7 00:00 ET
Brookline Capital Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $17
Moomoo NewsDec 5 12:31 ET · Ratings
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
BenzingaDec 5 08:01 ET

Comments

Jaguar8

Dec 8 18:55

NEWS SATURDAY

$Y-mAbs Therapeutics (YMAB.US)$
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...

Trytosaveabit

Dec 8 15:51

Watching Monday/week 12/9! Data released Saturday and more to come Monday 12/9/24

$Y-mAbs Therapeutics (YMAB.US)$ Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

Moomoo AI

Mar 24 10:01

Recent insider selling at Y-mAbs Therapeutics may indicate insiders believe shares are overpriced. The absence of insider purchases in the past year and low insider ownership warrant caution.

Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders

Moomoo AI

Mar 3 08:57

The company's cash runway and revenue growth are positive. Its cash burn relative to market capitalisation is low, indicating potential for more cash raising with minimal dilution or borrowing. The company's cash burn is not a concern, suggesting it is well-positioned for continued growth funding.